ATS 2018—Dupilumab reduces steroid dependence in severe asthma


  • Sean Henahan
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab, a fully human anti–interleukin-4 receptor α monoclonal antibody, appears to offer safe and effective treatment of severe asthma while significantly reducing oral glucocorticosteroid dependence.

Why this matters

  • Oral glucocorticoids are a mainstay of asthma treatment.
  • However, they can produce significant multiorgan toxic effects and broad immunosuppression.
  • Newer biologic agents appear to offer the promise of improving treatment without the side effects seen with oral glucocorticoid treatment.

Study design

  • The Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma (VENTURE) trial was an international, randomized, double-blind, placebo-controlled, phase 3 trial.
  • 210 patients with oral glucocorticoid-treated asthma received add-on dupilumab (at a dose of 300 mg) or placebo every 2 weeks for 24 weeks.
  • After a glucocorticoid dose-adjustment period before randomization, glucocorticoid doses were adjusted in a downward trend from week 4 to week 20 and then maintained at a stable dose for 4 weeks.
  • The study was funded by Sanofi and Regeneron Pharmaceuticals.

Key results

  • Dupilumab recipients saw a 70.1% reduction in glucocorticoid use compared with a reduction of 41.9% among placebo recipients (P<.001>
  • Dupilumab treatment resulted in a severe exacerbation rate that was 59% lower than that in the placebo group and resulted in an FEV1 that was 0.22 L higher.
  • Dupilumab was safe and well-tolerated.

Limitations

  • Dupilumab is very expensive, and healthcare systems may need convincing about the cost-efficacy.

 

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit